About KINTOR PHARMA-B Company

We are an innovative drug company in clinical development in China dedicated to addressing diseases that do not meet clinical needs, particularly androgen receptor-related (or AR-related) diseases. We are committed to being a leading company in the research, development and commercialization of innovative therapies. We have developed seven clinical-stage drugs under development. frethane (KX-826) Frethane (KX-826) is an AR antagonist. We are currently developing furatane as a potential first-of-its-kind topical treatment for androgenic alopecia (AGA) and acne. AR-PROTAC compound (GT20029) GT20029 is an AR-PROTAC compound for external use developed using the Group's proprietary PROTAC platform. We are currently developing GT20029 to treat hair loss and acne. procluramide (GT0918) Pucluramide (GT0918) has the potential to become a second-generation AR antagonist of the best drug in its class. We are currently developing proclomide to treat COVID-19, mCRPC, and AR+ metastatic breast cancer. HedgeHog/smO inhibitors (GT1708F) The hedgehog/smo inhibitor (GT1708F) is an inhibitor of the hedgehog signal transduction pathway. We are currently developing GT1708F mainly for the treatment of idiopathic pulmonary fibrosis (IPF) and hematological tumors. Ditoxetyl (GT0486) Ditosetil (GT0486) is a PI3K/mTOR signaling pathway inhibitor and is a second-generation mTOR inhibitor. We are currently developing GT0486 mainly for treating metastatic solid tumors such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC). ALK-1 antibody (GT90001) The ALK-1 antibody is a new anti-angiogenesis inhibitor that we obtained exclusive global approval from Pfizer in 2018 and is a new biological target for the world. We are developing ALK-1 antibodies to treat metastatic HCC and various solid tumors. PD-L1/TGF-β (GT90008) PD-L1/TGF-beta (GT90008) is a double target antibody composed of a PD-L1 antagonist antibody and a TGF-beta extracellular domain. It has high activity of simultaneously inhibiting PD-L1 and TGF-beta. It has the potential to treat a variety of solid tumors, including non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-related tumors (such as cervical cancer), and may be the best drug of its kind.